Cell-based assay for screening 11β-hydroxysteroid dehydrogenase 1 inhibitors

Analytical Biochemistry

Volumn 392, Issue 2, 2009, Pages 110-116

  Cho, Young Sik ^a   Kim, Chi Hyun ^a   Cheon, Hyae Gyeong ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

11 Hydroxysteroid dehydrogenase 1; Cell based assay; High throughput screening; Homogeneous time resolved fluorescence assay; Myotube

Indexed keywords

AMINO ACIDS; BIOCHEMISTRY; CELL CULTURE; DRUG PRODUCTS; ENZYME ACTIVITY; FLUORESCENCE; HORMONES; MUSCLE; RNA;

CELL-BASED ASSAYS; HIGH THROUGHPUT SCREENING; HOMOGENEOUS TIME-RESOLVED FLUORESCENCE ASSAYS; HYDROXYSTEROID DEHYDROGENASE; MYOTUBES;

CELLS;

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR; CARBENOXOLONE; CORTISONE; ENZYME INHIBITOR; GLUCOCORTICOID; GLUTAMATE AMMONIA LIGASE; HYDROCORTISONE; INTERLEUKIN 6; MESSENGER RNA; MIFEPRISTONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; FLUORESCENCE ANALYSIS; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; IC 50; MOUSE; MUSCLE CELL; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE;

MURINAE;

EID: 67650482320     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2009.04.038     Document Type: Article

References (20)

1. Wake D.J., and Walker B.R. 11β-Hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Mol. Cell. Endocrinol. 215 (2004) 45-54
2. Arampatzis S., Kadereit B., Schuster D., Balazs Z., Schweizer R.A., Frey F.J., Langer T., and Odermatt A. Comparative enzymology of 11β-hydroxysteroid dehydrogenase type 1 from six species. J. Mol. Endocrinol. 35 (2005) 89-101
3. Monder C. The forms and functions of 11β-hydroxysteroid dehydrogenase. J. Steroid Biochem. Mol. Biol. 45 (1993) 161-165
4. Stewart P.M. Tissue-specific Cushing's syndrome, 11β-hydroxysteroid dehydrogenases, and the redefinition of corticosteroid hormone action. Eur. J. Endocrinol. 149 (2003) 163-168
5. Walker B.R. 11β-Hydroxysteroid dehydrogenase type 1 in obesity. Obes. Res. 12 (2004) 1-3
6. Xiang J., Ipek M., Suri V., Massefski W., Pan N., Ge Y., Tam M., Xing Y., Tobin J.F., Xu X., and Tam S. Synthesis and biological evaluation of sulfonamidooxazoles and β-keto sulfones: selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. Lett. 15 (2005) 2865-2869
7. P.J. Barton, D.S. Clarke, C.D. Davies, R.B. Hargreaves, J.E. Pease, M.T. Rankine, World patent WO2004/011410 (A1), Chemical Compounds, 2004.
8. Barf T., Vallgarda J., Emond R., Haggstrom C., Kurz G., Nygren A., Larwood V., Mosialou E., Axelsson K., Olsson R., Engblom L., Edling N., Ronquist-Nii Y., Ohman B., Alberts P., and Abrahmsen L. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs: discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 45 (2002) 3813-3815
9. Xu R., Sang B.C., Navre M., and Kassel D.B. Cell-based assay for screening 11β-hydroxysteroid dehydrogenase inhibitors using liquid chromatography/tandem mass spectrometry detection. Rapid Commun. Mass Spectrom. 20 (2006) 1643-1647
10. Carballo-Jane E., Pandit S., Santoro J.C., Freund C., Luell S., Harris G., Forrest M.J., and Sitlani A.J. Skeletal muscle: a dual system to measure glucocorticoid-dependent transactivation and transrepression of gene regulation. J. Steroid Biochem. Mol. Biol. 88 (2004) 191-201
11. Barnes P.J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci. (Lond.) 94 (1998) 557-572
12. Diamond M.I., Miner J.N., Yoshinaga S.K., and Yamamoto K.R. Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 249 (1990) 1266-1272
13. Wang D.Y., Lu Q., Walsh S.L., Payne L., Modha S.S., Scott M.J., Sweitzer T.D., Ames R.S., and Krosky D.J. Development of a high-throughput cell-based assay for 11β-hydroxysteroid dehydrogenase type 1 using BacMam technology. Mol. Biotechnol. 39 (2008) 127-134
14. Zhang J.H., Chung T.D.Y., and Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4 (1999) 67-73
15. Solly K., Mundt S.S., Zokian H.J., Ding G.J.F., Vosatka A.H., Strulovici B., and Zheng W. High-throughput screening of 11β-hydroxysteroid dehydrogenase type 1 in scintillation proximity assay format. Assay Drug Dev. Technol. 3 (2005) 377-384
16. Andrews R.C., Rooyackers O., and Walker B.R. Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J. Clin. Endocrinol. Metab. 88 (2003) 285-291
17. Alberts P., Engblom L., Edling N., Forsgren M., Klingtrom G., Larsson C., Ronquist-Nii Y., Ohman B., and Abrahmsen L. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45 (2002) 1528-1532
18. R. Thieringer, J.M. Balkovec, H.Y. Chen, E. Frazier, C.B. Le Grand, Z. Li, J.M. Metzger, S.S. Mundt, C.N. Nunes, M. Strowski, S.H. Olson, N. Robertson, A.M. Strack, J.M. Schaeffer, B.B. Zhang, A. Hermanowski-Vosatka, A novel non-steroidal inhibitor of 11β-hydroxysteroid dehydrogenase type 1 improves features of metabolic syndrome in murine disease models, in: 23rd Joint Meeting of the British Endocrine Societies with the European Federation of Endocrine Societies, Brighton, UK, 2004.
19. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensible?. Cell 93 (1998) 487-490
20. Honer C., Nam K., Fink C., Marshall P., Ksander G., Chatelain R.E., Cornell W., Steele R., Schweitzer R., and Schumacher C. Glucocorticoid receptor antagonism by cyproterone acetate and RU486. Mol. Pharmacol. 63 (2003) 1012-1020